Literature DB >> 373912

Prognosis and treatment of acute lymphoblastic leukemia. Study of 650 patients.

C Jacquillat, M Weil, M F Auclerc, C Chastang, G Flandrin, V Izrael, G Schaison, L Degos, M Boiron, J Bernard.   

Abstract

The complete hematological remission (CHR) rate, duration of remission and survival were studied in relation to age, peripheral blast cell (PBC) count, presence or absence of tumor masses, cytological type, and treatment in 650 patients with acute lymphoblastic leukemia. Prognostic factors were considered separately and divided into prognostic classes. Age and PCB count correlated with both the rate and the duration of CHR. This correlation was still observed for more recent treatment schedules though it appears to be becoming progressively less significant. Meningeal relapses were more common in patients less than 1 year old and in those with a high PCB count. It is suggested that stratification of patients according to such factors as age, PCB count, presence or absence of tumor, and cytological type might be necessary for the design of new treatment protocols and for the evaluation of their results.

Entities:  

Mesh:

Year:  1978        PMID: 373912     DOI: 10.1007/bf00254045

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Antisera to acute lymphoblastic leukemia cells.

Authors:  M F Greaves; G Brown; N T Rapson; T A Lister
Journal:  Clin Immunol Immunopathol       Date:  1975-05

2.  On the usefulness of PAS reaction for the prognosis of acute lymphoblastic leukemia.

Authors:  E Ascari; G Marini; R Invernizzi; G Ippoliti; G Casirola; G Fontana; S C Rizzo
Journal:  Haematologica       Date:  1975-09       Impact factor: 9.941

3.  Five-year survivors among children with acute leukemia in Japan.

Authors:  T Izawa; T Yamashiro; K Aoki; M Taki; H Kamiya
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

4.  Evaluation of 216 four-year survivors of acute leukemia.

Authors:  C Jacquillat; M Weil; M F Gemon; V Izrael; G Schaison; G Auclerc; A R Ablin; G Flandrin; J Tanzer; A Bussel; C Weisgerber; C Dresch; Y Najean; M Goudemand; M Seligmann; M Boiron; J Bernard
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

5.  Cyclic chemotherapy in acute lymphoblastic leukaemia of childhood: 5-year survivals.

Authors:  M R Vowels; M L Willoughby
Journal:  Arch Dis Child       Date:  1973-06       Impact factor: 3.791

6.  Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia.

Authors:  W A Bleyer; J C Drake; B A Chabner
Journal:  N Engl J Med       Date:  1973-10-11       Impact factor: 91.245

7.  Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris).

Authors:  C Jacquillat; M Weil; M F Gemon; G Auclerc; J P Loisel; J Delobel; G Flandrin; G Schaison; V Izrael; A Bussel; C Dresch; C Weisgerber; D Rain; J Tanzer; Y Najean; M Seligmann; M Boiron; J Bernard
Journal:  Cancer Res       Date:  1973-12       Impact factor: 12.701

8.  Acute lymphocytic leukemia in children.

Authors:  J V Simone; R J Aur; H O Hustu; M Verzosa
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

9.  Prognostic value of the periodic acid-schiff (PAS) reaction in acute lymphoblastic leukemia.

Authors:  G B Humphrey; M E Nesbit; R D Brunning
Journal:  Am J Clin Pathol       Date:  1974-03       Impact factor: 2.493

10.  Acute lymphoblastic leukaemia: a heterogenous disease.

Authors:  D G Haegert; J Stuart; J L Smith
Journal:  Br Med J       Date:  1975-02-08
View more
  1 in total

1.  Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).

Authors:  J Donadieu; M F Auclerc; A Baruchel; Y Perel; P Bordigoni; J Landman-Parker; T Leblanc; G Cornu; D Sommelet; G Leverger; G Schaison; C Hill
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.